Biomarkers in Drug Development

Biomarkers in Drug Development
Author :
Publisher : Wiley
Total Pages : 800
Release :
ISBN-10 : 0470169273
ISBN-13 : 9780470169278
Rating : 4/5 (73 Downloads)

Book Synopsis Biomarkers in Drug Development by : Michael R. Bleavins

Download or read book Biomarkers in Drug Development written by Michael R. Bleavins and published by Wiley. This book was released on 2010-02-15 with total page 800 pages. Available in PDF, EPUB and Kindle. Book excerpt: Discover how biomarkers can boost the success rate of drug development efforts As pharmaceutical companies struggle to improve the success rate and cost-effectiveness of the drug development process, biomarkers have emerged as a valuable tool. This book synthesizes and reviews the latest efforts to identify, develop, and integrate biomarkers as a key strategy in translational medicine and the drug development process. Filled with case studies, the book demonstrates how biomarkers can improve drug development timelines, lower costs, facilitate better compound selection, reduce late-stage attrition, and open the door to personalized medicine. Biomarkers in Drug Development is divided into eight parts: Part One offers an overview of biomarkers and their role in drug development. Part Two highlights important technologies to help researchers identify new biomarkers. Part Three examines the characterization and validation process for both drugs and diagnostics, and provides practical advice on appropriate statistical methods to ensure that biomarkers fulfill their intended purpose. Parts Four through Six examine the application of biomarkers in discovery, preclinical safety assessment, clinical trials, and translational medicine. Part Seven focuses on lessons learned and the practical aspects of implementing biomarkers in drug development programs. Part Eight explores future trends and issues, including data integration, personalized medicine, and ethical concerns. Each of the thirty-eight chapters was contributed by one or more leading experts, including scientists from biotechnology and pharmaceutical firms, academia, and the U.S. Food and Drug Administration. Their contributions offer pharmaceutical and clinical researchers the most up-to-date understanding of the strategies used for and applications of biomarkers in drug development.


Biomarkers in Drug Development Related Books

Genomic Biomarkers for Pharmaceutical Development
Language: en
Pages: 203
Authors: Yihong Yao
Categories: Medical
Type: BOOK - Published: 2013-07-16 - Publisher: Academic Press

DOWNLOAD EBOOK

Genomic Biomarkers for Pharmaceutical Development: Advancing Personalized Health Care provides an in-depth review of the state of translational science across a
Genomic Biomarkers for Pharmaceutical Development
Language: en
Pages: 46
Authors: Yuping Wang
Categories: Medical
Type: BOOK - Published: 2013-07-16 - Publisher: Elsevier Inc. Chapters

DOWNLOAD EBOOK

Although we have seen increased spending on drug research and development, the submission of new drug applications to the US Food and Drug Administration (FDA)
Biomarkers in Drug Discovery and Development
Language: en
Pages: 624
Authors: Ramin Rahbari
Categories: Medical
Type: BOOK - Published: 2020-02-28 - Publisher: John Wiley & Sons

DOWNLOAD EBOOK

This book continues the legacy of a well-established reference within the pharmaceutical industry – providing perspective, covering recent developments in tec
Genomics in Drug Discovery and Development
Language: en
Pages: 496
Authors: Dimitri Semizarov
Categories: Medical
Type: BOOK - Published: 2008-11-03 - Publisher: John Wiley & Sons

DOWNLOAD EBOOK

Early characterization of toxicity and efficacy would significantly impact the overall productivity of pharmaceutical R&D and reduce drug candidate attrition an
Genomic Biomarkers for Pharmaceutical Development
Language: en
Pages: 41
Authors: Koustubh Ranade
Categories: Medical
Type: BOOK - Published: 2013-07-16 - Publisher: Elsevier Inc. Chapters

DOWNLOAD EBOOK

Despite the large and ever-growing investment in pharmaceutical R&D, the number of innovative new medicines that meet significant unmet medical needs has been s